Stocks Health care KRYS
NASDAQ · Health careKrystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. brought in $470M of revenue over the twelve months to September 30, 2026, up 26.0% from a year earlier. Net income was $225.2M, a net margin of 47.9%. Operating cash flow minus capital spending left $188.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $462.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 2, 2026.
Key facts about Krystal Biotech, Inc.
- Net worth
- Krystal Biotech, Inc. has a market value (market cap) of $9.1B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $389.1M (+33.9% year on year), with net income of $204.8M. Over the 12 months to September 30, 2026: revenue $470M, net income $225.2M.
- Cash flow
- In fiscal 2025 operations brought in $200.9M of cash; after $12M of capital spending, free cash flow was $188.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 2, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Krystal Biotech, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Krystal Biotech, Inc. does
Krystal Biotech, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KRYS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $389.1M | $204.8M | $6.84 | $188.9M |
| 2024 | $290.5M | $89.2M | $3.00 | $119.2M |
| 2023 | $50.7M | $10.9M | $0.39 | -$100.6M |
| 2021 | $0 | -$140M | -$5.49 | -$153.5M |
| 2021 | $0 | -$69.6M | -$3.13 | -$116.3M |
| 2020 | n/a | -$32.2M | -$1.71 | -$40.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KRYS ranks in Health care
Latest SEC filings
What Krystal Biotech, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 2, 2026
- November 2, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 30% to $127.3M versus the same quarter last year; diluted EPS $2.05 versus $2.66.
- October 30, 2026Passive stake changed SCHEDULE 13G/A
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 15, 2026
- August 3, 2026
- August 3, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 24% to $119.2M versus the same quarter last year; diluted EPS $1.79 versus $1.29.
- July 21, 2026Other event 8-K
- May 20, 2026
- May 4, 2026Passive stake changed SCHEDULE 13G/A
What is KRYS worth? A DCF from its reported cash flow
Insider trades
What the people running Krystal Biotech, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $26.2M worth of shares in the last 90 days and bought none on the open market. Most of the selling (69%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 520 | $184.4K |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 2,029 | $721.5K |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,297 | $1.2M |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,981 | $1.4M |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,143 | $1.1M |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 3,357 | $1.2M |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 2,266 | $816.8K |
| September 4, 2026 | Krishnan Krish SPresident and CEO, Director, 10% owner | Soldpre-planned (10b5-1) | 1,214 | $439K |
Who owns KRYS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 11.6% | October 27, 2026 |
| Krish S. Krishnan13G, passive with 1 related filers | 11.5% | May 4, 2026 |
| Vanguard Portfolio Management13G, passive | 5.05% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 422 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 4,418,197 | +44,210 |
| BlackRock, Inc. | 4,181,432 | +240,976 |
| Avoro Capital Advisors LLC | 2,888,888 | 0 |
| Vanguard Portfolio Management LLC | 1,574,905 | +118,178 |
| State Street Corp | 1,351,158 | +36,724 |
| Vanguard Capital Management LLC | 1,240,567 | +75,243 |
| Soleus Capital Management, L.P. | 939,254 | -213,833 |
| Capital World Investors | 777,843 | -46,877 |
| Geode Capital Management, LLC | 698,993 | +55,018 |
| Hood River Capital Management LLC | 663,375 | +43,789 |
| Redmile Group, LLC | 632,005 | -41,500 |
| William Blair Investment Management, LLC | 570,153 | +162,975 |
| Frazier Life Sciences Management, L.P. | 481,307 | 0 |
| Dimensional Fund Advisors LP | 476,038 | +7,048 |
| First Trust Advisors LP | 324,900 | -25,621 |
| Invesco Ltd. | 324,755 | +73,382 |
| Goldman Sachs Group Inc | 298,841 | +83,892 |
| Northern Trust Corp | 283,784 | +31,321 |
| Franklin Resources Inc | 261,917 | +82,652 |
| Norges Bank | 259,030 | new |
Insiders
5 insiders reported holding 5,723,755 shares in total, about $1.75B at the last price.
| Holder | Shares |
|---|---|
| Krishnan SumaPresident, R&D, Director, 10% owner | 2,802,3981,500,253 held indirectly |
| Krishnan Krish SPresident and CEO, Director, 10% owner | 2,775,6981,428,155 held indirectly |
| Janney DanielDirector | 73,29373,293 held indirectly |
| Rossi Dino ADirector | 50,000 |
| Romano KathrynChief Accounting Officer | 22,366 |
Questions about KRYS
What does Krystal Biotech, Inc. do?
Krystal Biotech, Inc. is a company in the Health care sector, listed on NASDAQ as KRYS. Its shares trade on NASDAQ under the ticker KRYS.
What is Krystal Biotech, Inc.'s net worth?
Krystal Biotech, Inc. has a market value (market cap) of $9.1B at the latest share price, and shareholders' equity of $1.4B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Krystal Biotech, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $225.2M on revenue of $470M, a net margin of 47.9%.
How much revenue does Krystal Biotech, Inc. make?
Over the twelve months to September 30, 2026 Krystal Biotech, Inc. reported revenue of $470M. That is 26.0% more than a year earlier.
When did Krystal Biotech, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 2, 2026. It covers the period to September 30, 2026.
When is Krystal Biotech, Inc.'s next earnings report?
Krystal Biotech, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KRYS with
Follow KRYS
Get an email when Krystal Biotech, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Krystal Biotech, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.